The paradox that NAD+ declines systemically yet rises within senescent cells suggests a compartmentalized role for this cofactor in sustaining the senescence‑associated secretory phenotype (SASP). Recent data show that SASP factors (IL‑6, TNF‑α) induce CD38 on neighboring cells, driving paracellular NAD+ depletion, while inside senescent cells NAMPT‑mediated NAD+ elevation suppresses AMPK‑p53 and permits p38 MAPK‑dependent NF‑κB activation, thereby amplifying SASP {6}. This implies that NAD+ is not merely a passive metabolite but an active fuel for the inflammatory program of senescent cells.

Hypothesis: In senescent cells, NAD+ directly enables the p38 MAPK‑NF‑κB axis by serving as a required cofactor for the NAD‑dependent enzyme SIRT2, which deacetylates and activates the MAPK kinase MKK3/6. Activated MKK3/6 phosphorylates p38 MAPK, which then phosphorylates the NF‑κB p65 subunit at Ser536, enhancing its transcriptional activity and driving SASP expression. Consequently, inhibiting NAMPT selectively in senescent cells will lower intracellular NAD+, reduce SIRT2 activity, blunt p38 MAPK signaling, and attenuate SASP without causing systemic NAD+ deficiency.

Testable predictions:

1. Genetic – Senocyte‑specific knockout of Nampt in aged mice (using p16‑3MR or p21‑Cre drivers) will decrease NAD+ levels isolated from p16^high^ cells by >40% {4} while leaving NAD+ in non‑senescent tissues unchanged. These mice will exhibit reduced plasma IL‑6, IL‑8, and TNF‑α levels and improved tissue histology compared with wild‑type controls.
2. Pharmacological – Delivery of a NAMPT inhibitor (e.g., FK866) conjugated to a senocyte‑targeting moiety (such as a galacto‑mannose nanoparticle that exploits elevated lysosomal β‑galactosidase in senescent cells) will lower SASP factor secretion in vitro in irradiated human fibroblasts and in vivo in progeroid Ercc1^−/−^ mice. Control liposomes lacking the targeting ligand will not affect SASP but will cause systemic NAD+ drop and associated toxicity.
3. Mechanistic – In senescent cells, SIRT2 immunoprecipitation will show increased association with MKK3/6 under high NAD+ conditions; SIRT2 knock‑down or pharmacological inhibition (AGK2) will phenocopy NAMPT loss, reducing p38 MAPK phosphorylation and NF‑κB p65 Ser536 acetylation, and diminishing IL‑6 mRNA expression. Rescue experiments adding exogenous NAD+ will restore SIRT2 activity and SASP only when SIRT2 is present.

Falsifiability: If senocyte‑specific NAMPT loss fails to lower SASP markers or if systemic NAD+ supplementation does not exacerbate inflammation in aged animals, the hypothesis would be refuted. Similarly, if SIRT2 inhibition does not affect p38 MAPK‑NF‑κB signaling in senescent cells, the proposed mechanistic link would be invalid.

Implications: This hypothesis reframes NAD+ not as a universal anti‑aging supplement but as a context‑dependent regulator whose manipulation must be spatially precise. Targeting the NAD+‑SIRT2‑p38 MAPK node in senescent cells could decouple the detrimental SASP from beneficial NAD+ functions in tissue repair and metabolism, offering a therapeutic avenue that avoids the pitfalls of blanket NAD+ repletion.